List of Excipients in API oxymetazoline hydrochloride
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing oxymetazoline hydrochloride
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Allergan Inc | RHOFADE | oxymetazoline hydrochloride | 0023-5300 | ANHYDROUS CITRIC ACID | |
| Allergan Inc | RHOFADE | oxymetazoline hydrochloride | 0023-5300 | BUTYLATED HYDROXYTOLUENE | |
| Allergan Inc | RHOFADE | oxymetazoline hydrochloride | 0023-5300 | CETEARETH-25 | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing oxymetazoline hydrochloride
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 | ANHYDROUS CITRIC ACID |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 | BUTYLATED HYDROXYTOLUENE |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 | CETEARETH-25 |
| >Company | >Ingredient | >NDC | >Excipient |
Detailed excipient profiles for oxymetazoline hydrochloride
Excipient focus: ANHYDROUS CITRIC ACID
oxymetazoline hydrochloride drug variants containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYLATED HYDROXYTOLUENE
oxymetazoline hydrochloride drug variants containing BUTYLATED HYDROXYTOLUENE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing BUTYLATED HYDROXYTOLUENE
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: CALCIUM CHLORIDE
oxymetazoline hydrochloride drug variants containing CALCIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing CALCIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
Excipient focus: CETEARETH-25
oxymetazoline hydrochloride drug variants containing CETEARETH-25
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing CETEARETH-25
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: CETEARETH-6
oxymetazoline hydrochloride drug variants containing CETEARETH-6
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing CETEARETH-6
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: CETOSTEARYL ALCOHOL
oxymetazoline hydrochloride drug variants containing CETOSTEARYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing CETOSTEARYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: DIISOPROPYL ADIPATE
oxymetazoline hydrochloride drug variants containing DIISOPROPYL ADIPATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing DIISOPROPYL ADIPATE
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: EDETATE DISODIUM
oxymetazoline hydrochloride drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCOL STEARATE
oxymetazoline hydrochloride drug variants containing GLYCOL STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| Aclaris Therapeutics Inc | oxymetazoline hydrochloride | 71180-003 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing GLYCOL STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
oxymetazoline hydrochloride drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
oxymetazoline hydrochloride drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
Excipient focus: LANOLIN
oxymetazoline hydrochloride drug variants containing LANOLIN
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing LANOLIN
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM CHLORIDE
oxymetazoline hydrochloride drug variants containing MAGNESIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing MAGNESIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES
oxymetazoline hydrochloride drug variants containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: METHYLPARABEN
oxymetazoline hydrochloride drug variants containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: OLEYL ALCOHOL
oxymetazoline hydrochloride drug variants containing OLEYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing OLEYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: PEG-32 STEARATE
oxymetazoline hydrochloride drug variants containing PEG-32 STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| Aclaris Therapeutics Inc | oxymetazoline hydrochloride | 71180-003 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing PEG-32 STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: PEG-6 STEARATE
oxymetazoline hydrochloride drug variants containing PEG-6 STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| Aclaris Therapeutics Inc | oxymetazoline hydrochloride | 71180-003 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing PEG-6 STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: PHENOXYETHANOL
oxymetazoline hydrochloride drug variants containing PHENOXYETHANOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing PHENOXYETHANOL
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 300
oxymetazoline hydrochloride drug variants containing POLYETHYLENE GLYCOL 300
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing POLYETHYLENE GLYCOL 300
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 60
oxymetazoline hydrochloride drug variants containing POLYSORBATE 60
| Company | Ingredient | NDC |
|---|---|---|
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing POLYSORBATE 60
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| Aclaris Therapeutics Inc | oxymetazoline hydrochloride | 71180-003 |
| >Company | >Ingredient | >NDC |
Excipient focus: POTASSIUM CHLORIDE
oxymetazoline hydrochloride drug variants containing POTASSIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing POTASSIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLPARABEN
oxymetazoline hydrochloride drug variants containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM ACETATE
oxymetazoline hydrochloride drug variants containing SODIUM ACETATE
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing SODIUM ACETATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CHLORIDE
oxymetazoline hydrochloride drug variants containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CITRATE
oxymetazoline hydrochloride drug variants containing SODIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing SODIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITAN MONOSTEARATE
oxymetazoline hydrochloride drug variants containing SORBITAN MONOSTEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing SORBITAN MONOSTEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| Aclaris Therapeutics Inc | oxymetazoline hydrochloride | 71180-003 |
| >Company | >Ingredient | >NDC |
Excipient focus: STEARYL ALCOHOL
oxymetazoline hydrochloride drug variants containing STEARYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing STEARYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: TRISODIUM CITRATE DIHYDRATE
oxymetazoline hydrochloride drug variants containing TRISODIUM CITRATE DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing TRISODIUM CITRATE DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| RVL Pharmaceuticals Inc | oxymetazoline hydrochloride ophthalmic | 73687-062 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
oxymetazoline hydrochloride drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | oxymetazoline hydrochloride | 0023-5300 |
| Taro Pharmaceuticals USA Inc | oxymetazoline hydrochloride | 51672-1405 |
| Mayne Pharma | oxymetazoline hydrochloride | 51862-765 |
| >Company | >Ingredient | >NDC |
oxymetazoline hydrochloride drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
